James Harding MD

James J. Harding, MD, is an Associate Attending on the Gastrointestinal Oncology and Early Drug Development Services in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He completed his Internal Medicine training at New York Presbyterian Hospital and his fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center.

Dr. Harding was recruited to the faculty in 2013, and his clinic focuses on the care of patients with hepatobiliary tumors and other digestive malignancies. His clinical and translational research focuses on developing new drugs for patients with tumors of the liver and biliary tree.

Dr. Harding is an Associate Chair of the Memorial Sloan Kettering Institutional Review Board and Privacy Board and a Director on the Early Drug Development Service. His research and training have been supported by competitive peer-reviewed funding and awards from the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the Howard Hughes Medical Institute, the Society for Memorial Sloan Kettering, Cycle for Survival, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. He has published over 270 original peer-reviewed manuscripts and abstracts with collaborators focused on liver cancer, bile duct cancer, and drug development.